The Alzheimer's Disease Anti-inflammatory Prevention Trial - Follow-up Study (ADAPT-FS) is continued observation of the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT), a randomized, parallel, placebo-controlled, multicenter trial designed to test the efficacy of a non-selective non-steroidal anti-inflammatory drug and a selective COX-2 inhibitor for the prevention of Alzheimer's disease and attenuation of age related cognitive decline.  The treatment regimens, which were administered in parallel, are: naproxen sodium (220 mg b.i.d.), celecoxib (200 mg b.i.d.) and matching placebos.  ADAPT enrolled 2,528 participants who screened negative for dementia, were age 70 or older at enrollment and had a history of Alzheimer-like dementia in a first degree relative.  Participants have been unmasked to their original treatment assignment.

ADAPT-FS datasets are available upon request. All requests must be vetted by the ADAPT-FS Study Officers and must include an analysis plan. If the request is approved the requestor must have IRB approval to receive ADAPT data. Request can be submitted to the address provided in the "Contacts" page.

Home | Centers | Contacts | Documents | Links | Presentations | Publications